NeuroHealing Appoints David Gwynne, VP Business Development

Initial Focus on NH02D Program for the Treatment of Premature Ejaculation Newton, Massachusetts – February 2, 2009. NeuroHealing Pharmaceuticals, a private, clinical stage company developing innovative drug treatments for specialty indications based on repositioning neurologically active compounds, today announced the appointment of David Gwynne, Ph.D. as vice president, business development, responsible for NeuroHealing’s NH02D program…

Details
NeuroHealing

NeuroHealing Pharmaceuticals to Present at Drug Repositioning Summit in Boston, October 6-7, 2008

Newton, Massachusetts, September 24, 2008. NeuroHealing Pharmaceuticals, a private clinical stage company developing innovative products for individuals with chronic brain injuries and neurodegenerative diseases, will present a talk entitled: “There’s Still Low Hanging Fruit: Three Repositioned Drugs in Clinical Testing for Brain Injury Patients” at the 3rd Annual Drug Repositioning Summit: Finding New Routes to…

Details
NeuroHealing

Industry Leaders Select NeuroHealing’s NH001 Among Top 10 Most Promising Neuroscience Projects Available for Partnering

Newton, Massachusetts – August 11, 2008 – NeuroHealing Pharmaceuticals, a private clinical stage company developing products for individuals with chronic brain injuries and neurodegenerative diseases, today announced that NH001 has been chosen by Windhover Information and independent expert Harry Tracy, as one of the top 10 most interesting neuroscience projects in development available for strategic…

Details
NeuroHealing

Life Science Angels Makes Additional Investment in NeuroHealing Pharmaceuticals

Newton, Massachusetts – July 22, 2008 Life Science Angels (LSA), a Bay Area healthcare angel investment group focused on biotechnology and medical device companies, has made a further investment in NeuroHealing Pharmaceuticals. With this third round since March 2006, LSA has invested over $650,000 in NeuroHealing. NeuroHealing Pharmaceuticals is a specialty clinical stage neuroscience company…

Details
NeuroHealing

NeuroHealing Pharmaceuticals Receives Grant from the FDA Office of Orphan Drugs for Clinical Development of NH001 to Treat Patients in a Vegetative and Minimally Conscious State

Receipt of Peer-Reviewed Competitive Grant Acknowledges Promise of NH001 As a Treatment for Patients in a Comatose State following a Traumatic Brain Injury Newton, Massachusetts – July 16, 2008 NeuroHealing Pharmaceuticals, a company developing products for individuals with chronic brain injuries, today announced that the Food and Drug Administration (FDA) has awarded the company a…

Details
NeuroHealing